Erin Bastick
Erin Bastick is a PharmD Candidate 2016, Ohio Northern University, Ada, Ohio, and an inpatient intern at University Hospitals, Cleveland.
New antibacterial treatment for plague approved
FDA has approved moxifloxacin (Avelox) for the treatment of patients with plague. Avelox has been approved under the Animal Efficacy Rule, because it was not ethical to conduct human trials.
FDA approves Breo Ellipta for treatment for asthma in adults
FDA has approved fluticasone furoate/ vilanterol (Breo Ellipta) for the treatment of asthma in adults. Breo Ellipta is a fixed-dose combination of fluticasone furoate, which is an inhaled corticosteroid (ICS), and vilanterol, which is a long-acting beta 2 agonist (LABA). The fluticasone reduces inflammation while the vilanterol acts to open the airways. Breo Ellipta is administered using the Ellipta dry powder inhaler and comes in two strengths, 100/25 mcg and 200/25 mcg.
FDA approves Cyramza for treatment of metastatic colorectal cancer
FDA has approved Cyramza (ramucirumab, Eli Lilly) injection for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy.
FDA approves Corlanor to treat heart failure
FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure. Corlanor is an antianginal agent approved for use in patients who have chronic heart failure caused by the lower-left part of the heart not contracting well.
FDA approves breath test to help diagnose gastroparesis
The FDA has approved the Gastric Emptying Breath Test (GEBT), manufactured by Advanced Breath Diagnostics, a new, non-invasive test used to help diagnose gastroparesis.
Strep A rapid molecular test gets FDA clearance
FDA has granted marketing clearance for Alere I Strep A Rapid Molecular Test (Alere). The Alere I molecular test initially received marketing clearance in June 2014 for the detection and differentiation of influenza A and B virus, and in January 2015, the test became the first-ever molecular test to receive a Clinical Laboratory Improvement Amendments (CLIA) waiver from the FDA.
FDA approves label update for Zytiga
FDA has approved label update for abiraterone acetate (Zytiga, Janssen) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
FDA approves new administration option for Brilinta
FDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients.
FDA expanded approval of aflibercept injection to treat diabetic retinopathy
FDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
FDA warns consumers about OTC homeopathic asthma treatments
The FDA warns consumers not to rely on the use of over-the-counter homeopathic therapies for the treatment of asthma. Without appropriate management, asthma could lead to a life-threatening asthma attack. Homeopathic remedies have not be evaluated by the FDA and may interfere with asthma management.